Jon Stokes is on a mission to kill dangerous bacteria. His secret weapon? Artificial intelligence.

Last year, McMaster researcher Jon Stokes used AI to discover abaucin, a potent new drug candidate that targets Acinetobacter baumannii, one of the most dangerous drug-resistant bacteria in the world. He continued that work when he invented an AI algorithm that can design even more new antibiotics that target A. baumannii.

And recently, Stokes founded Stoked Bio, a new biotech startup company that focuses on ensuring breakthrough medicines make it out of the lab and into the patients who need them the most.

Want to learn more?

Sign up to receive future communications from McMaster University

Meet John Valliant, the scientist-entrepreneur behind one of the largest acquisitions in Canadian university history.

Fusion Pharmaceuticals, a radiopharmaceutical company founded by McMaster researcher John Valliant, uses nuclear medicine to develop next-generation cancer therapies that target cancer cells directly, providing patients with more effective and precise treatments with reduced side effects.

And it was recently acquired by AstraZeneca for $2 billion.

An idea scribbled on a napkin grew into a company that not only provides better treatments for cancer patients; it also strengthens local and national economics and trains the next generation of scientists.

Want to learn more?

Sign up to receive future communications from McMaster University